5637

5637 (Bladder Cancer CDX Model)

The 5637 bladder cancer cell line was derived from a grade II urinary bladder carcinoma. Classified as a transitional cell carcinoma, it is widely used in studies of urothelial cancer. The model offers consistent growth and reproducibility, making it a reliable system for oncology research. Researchers use 5637 to explore new therapeutic approaches in bladder cancer. 

Key Features: 

• Derived from a human urinary bladder carcinoma (grade II). 

• Representative of transitional cell carcinoma.

• Moderate tumorigenicity in xenografts. 

• Useful for bladder cancer drug discovery and testing. 

Applications: 
5637 is applied in studies of urothelial carcinoma drug response and biomarker development. The model supports preclinical screening of chemotherapies and targeted therapies. Its consistency makes it valuable for reproducibility in research programs. Investigators often use 5637 to assess mechanisms of bladder cancer progression.